NSE: BIOCON · 26 October 2026
- Biocon Limited shares gained 1.64% on Monday, closing at ₹328.80 after moving between a day's low of ₹321.40 and a high of ₹329.75. The stock opened lower at ₹322.20 compared to its previous close of ₹323.50.
- Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This milestone builds upon prior agreements securing entry dates in the United States, Europe, the UK, Canada, and Japan. The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025.
- Trading volume was 1.16 times the 20-day average daily volume.
Why is Biocon Limited. share price rising on 26 October 2026?
Biocon Limited shares gained 1.64% on Monday, closing at ₹328.80 after moving between a day's low of ₹321.40 and a high of ₹329.75. The stock opened lower at ₹322.20 compared to its previous close of ₹323.50.
The broader market and sector backdrop provided supportive conditions for the move, as the benchmark Nifty rose 0.68% while the Nifty Pharma sector index advanced 1.76%. Biocon's session gains come against a backdrop of recent short-term weakness, having declined 5.84% over the preceding 5 trading days and 15.04% over the past 20 trading days.
Company disclosures showed that Biocon announced a license agreement with Janssen Sciences Ireland on October 26, 2026, clearing the way for the commercialization of Yesintek, its proposed biosimilar to Stelara, across multiple global markets including Australia, Brazil, China, and South Korea. This follows earlier announcements regarding global patent settlements and market entries, though broader market participation and sector strength also provided context for today's session.
30.28 lakh shares traded by 26 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 26.13 lakh shares (1.16 times). The five-day average daily volume was 26.32 lakh shares. Separately, the NSE report for 23 October 2026 showed 18.25 lakh shares delivered, representing 52.58% of that day’s traded volume. The same report recorded 51,014 trades.
Biocon shares rose 1.64% alongside strong performance in the broader pharmaceutical sector and following the announcement of international commercialization rights for its biosimilar portfolio. The move reflects positive sentiment in line with industry trends, coupled with stable cash trading volumes.
Latest Company Developments
Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This milestone builds upon prior agreements securing entry dates in the United States, Europe, the UK, Canada, and Japan. The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025.
Expanding commercialization rights across major international markets strengthens Biocon's global biosimilars footprint and long-term revenue potential in the autoimmune disease segment.
Biocon entered into a global settlement and license agreement with Genentech to resolve pending disputes and secure earliest licensed launch dates for Pebrilzo, a biosimilar to Perjeta. The agreement permits launches in the European Union and UK in the first quarter of calendar year 2027, the U.S. in the third quarter of calendar year 2028, and across various Rest of the World markets between calendar year 2026 and 2028.
Resolving litigation and locking in defined launch timelines removes regulatory uncertainty and provides clear visibility for the company's oncology biosimilars pipeline.
a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Communication regarding remittance of final dividend for the FY 2025-26.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 22.08% on 30 September 2026. This compares with 15.47% on 30 June 2026, a change of +6.61 percentage points.
The filing reported 40 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and regulatory timelines for the commercialization of Yesintek across newly licensed international markets.
- Updates regarding the planned rollout and patent settlement milestones for Pebrilzo in key regulated geographies.
- Delivery volume trends and cash market participation relative to the 20-day average volume of 3,028,217 shares.
- Performance of the Nifty Pharma sector index and broader market breadth following recent volatility.
Other Dated Coverage
- Biocon Limited. Share Price Today: Why BIOCON Is Falling 2.06% | 23 October 2026 — 23 October 2026
- Biocon in Focus After Global Patent Settlement for Pebrilzo | 15 October 2026 — 15 October 2026
- Biocon Limited. Share Price Today: Why BIOCON Is Rising 0.82% | 14 October 2026 — 14 October 2026
More Biocon Limited. news and dated analysis →
Frequently Asked Questions
What is the latest Biocon Limited. company news?
Biocon signed a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This milestone builds upon prior agreements securing entry dates in the United States, Europe, the UK, Canada, and Japan. The reference brand, Stelara, recorded worldwide sales of $6.08 billion in 2025.
How strong was Biocon Limited.’s trading volume?
30.28 lakh shares traded, 1.16 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.